MacroGenics
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell MacroGenics and other ETFs, options, and stocks.About MGNX
MacroGenics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of antibody-based therapeutics for the treatment of cancer. Its product pipeline includes Margetuximab, Flotetuzumab, Retifanlimab, Enoblituzumab, Tebotelimab, MGC018, MGD019, IMGC936, and MGD014 for infectious diseases.
MGNX Key Statistics
Stock Snapshot
MacroGenics(MGNX) stock is priced at $3.52, giving the company a market capitalization of 220.54M. It carries a P/E multiple of -2.94.
On 2026-04-21, MacroGenics(MGNX) stock moved within a range of $3.46 to $3.66. With shares now at $3.52, the stock is trading +1.9% above its intraday low and -3.8% below the session's peak.
Trading activity shows a volume of 721.7K, compared to an average daily volume of 948.89K.
Over the past 52 weeks, MacroGenics(MGNX) stock has traded between a high of $3.88 and a low of $1.19.
Over the past 52 weeks, MacroGenics(MGNX) stock has traded between a high of $3.88 and a low of $1.19.
MGNX News
Barclays raised the firm’s price target on MacroGenics (MGNX) to $6 from $4 and keeps an Overweight rating on the shares. The firm adjusted ratings and targets...
MacroGenics Inc (MGNX) announced an update on their ongoing clinical study. Unlock hedge fund-level data and powerful investing tools for smarter, sharper deci...
Analyst ratings
50%
of 6 ratingsPeople also own
Similar Marketcap
This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.
Popular Stocks
This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset
Newly Listed
This list is generated by showing companies that recently went public.